23andMe’s crisis is DNA Spectrum’s gain. The rival genetic testing service released an announcement Tuesday, saying that while 23andMe has angered the FDA by promoting product claims it cannot support, the Phoenix, AZ, company “continues to be committed to the protection of consumers in genetic testing.”
DNA Spectrum’s announcement notes the company has a “cutting-edge lineup of genetic ancestry services,” and that it is ready to provide “the best personal genetics holiday gifts to share with family and friends.”
